Aura Biosciences, Inc.
AURANASDAQHealthcare● Active
$6.63
+$0.00(+0.00%)
Market Cap$425644515
P/E Ratio—
52W High$9.535
52W Low$4.73
Aura Biosciences, Inc. (AURA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AURA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.50
Est. -$0.40 · -25.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS
AURA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.46
Rev. $3.65B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.46
Rev. Est.$3.65B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.41 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.40 | -$0.50 | -25.0% | — | — | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$0.43 | -$0.37 | +13.9% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.46 | -$0.40 | +13.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.49 | -$0.47 | +4.1% | — | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.47 | -$0.55 | -17.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 24, 2025 | -$0.43 | -$0.52 | -20.9% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.44 | -$0.42 | +4.5% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.41
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.50
EPS Est.
-$0.40
EPS Surpr.
-25.0%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$0.37
EPS Est.
-$0.43
EPS Surpr.
+13.9%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.46
EPS Surpr.
+13.0%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.47
EPS Est.
-$0.49
EPS Surpr.
+4.1%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.55
EPS Est.
-$0.47
EPS Surpr.
-17.0%
Revenue
—
Q1 FY2025
Mar 24, 2025Miss
EPS Actual
-$0.52
EPS Est.
-$0.43
EPS Surpr.
-20.9%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.42
EPS Est.
-$0.44
EPS Surpr.
+4.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q3 FY2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q2 FY2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Q1 FY2027 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q4 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q3 FY2026 | $-0.37 | $-0.37 | $-0.37 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -25.0% | $8.40 | $8.19 | -2.50% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +13.9% | $6.27 | $6.20 | -1.12% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +13.0% | $5.57 | $5.53 | -0.72% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +4.1% | $6.94 | $7.23 | +4.18% |
| ▼ Q2 FY2025 | May 15, 2025 | -17.0% | $4.90 | $5.18 | +5.71% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -20.9% | $7.50 | $7.00 | -6.67% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +4.5% | $11.14 | $10.65 | -4.40% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +8.9% | $8.19 | $8.47 | +3.42% |
Q2 FY2026-2.50%
Report Date
May 11, 2026
EPS Beat/Miss
-25.0%
Price Before
$8.40
Price After
$8.19
Q1 FY2026-1.12%
Report Date
Mar 30, 2026
EPS Beat/Miss
+13.9%
Price Before
$6.27
Price After
$6.20
Q4 FY2025-0.72%
Report Date
Nov 13, 2025
EPS Beat/Miss
+13.0%
Price Before
$5.57
Price After
$5.53
Q3 FY2025+4.18%
Report Date
Aug 13, 2025
EPS Beat/Miss
+4.1%
Price Before
$6.94
Price After
$7.23
Q2 FY2025+5.71%
Report Date
May 15, 2025
EPS Beat/Miss
-17.0%
Price Before
$4.90
Price After
$5.18
Q1 FY2025-6.67%
Report Date
Mar 24, 2025
EPS Beat/Miss
-20.9%
Price Before
$7.50
Price After
$7.00
Q4 FY2024-4.40%
Report Date
Nov 12, 2024
EPS Beat/Miss
+4.5%
Price Before
$11.14
Price After
$10.65
Q3 FY2024+3.42%
Report Date
Aug 8, 2024
EPS Beat/Miss
+8.9%
Price Before
$8.19
Price After
$8.47
Avg Beat Reaction+0.27%
Avg Miss Reaction-1.15%
Beat Rate5 / 8 quarters
Largest Move-6.67% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AURA ends December
Aura Biosciences, Inc. (AURA) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.50 — missing the analyst consensus of $-0.40 by -25.0%. The next AURA earnings date is expected around September 1, 2026.
Each quarter, investors track AURA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AURA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AURA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AURA earnings · 5 questionsAura Biosciences, Inc.'s next earnings report is expected around September 1, 2026. AURA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AURA historically reports after market close (AMC).
AURA earnings datewhen is AURA earningsAURA next earnings datewhen does AURA report earningsAURA earnings calendar
▸ Source: FMP · Aura Biosciences, Inc. SEC filings · US GAAP · Aura Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026